Glenmark Pharmaceuticals
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Glenmark Pharmaceuticals is navigating a strategic transition from a generic-focused model to an innovation-led specialty pharmaceutical company, emphasizing oncology, respiratory, and dermatology. Management's confidence is bolstered by a robust R&D pipeline, highlighted by the successful AbbVie-ISB 2001 licensing deal, which positions the company for long-term revenue growth. Despite facing headwinds such as rising input costs and regulatory challenges, Glenmark's disciplined capital allocation and focus on high-margin products are expected to enhance operating leverage. Vista's financial outlook anticipates a revenue CAGR of 13-15% and EBITDA margins improving to 21-22% by FY27, supported by the expansion of branded products and new launches in key markets. However, macroeconomic pressures, including inflation and geopolitical instability, may impact margins. Over the next 12-24 months, key opportunities include the commercialization of innovative products and strategic partnerships, while watchpoints include execution risks and competitive pressures in both domestic and international markets
Why We Like This Stock
- Successful licensing deals and a strong R&D pipeline are expected to drive long-term revenue growth
- Management's focus on high-margin specialty products is likely to enhance operating leverage and profitability
- The anticipated expansion of branded products in key markets supports a robust revenue outlook
Things To Watch Out For
- Rising input costs and regulatory challenges may pressure profit margins
- Execution risks associated with the ambitious innovation strategy could hinder growth
- Increased competition in both domestic and international markets may impact pricing power
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 11,813 | 13,322 | 16,983 | 16,571 | 18,366 |
| Profit Before Tax (Cr.) | 936 | 1,772 | 4,251 | 3,861 | 4,245 |
| PBT Margin | 7.9% | 13.3% | 25.0% | 23.3% | 23.1% |
| Net Profit (Cr.) | -3,654 | 1,288 | 2,887 | 2,538 | 2,790 |
| Earnings Per Share | -132.0 | 45.7 | 102.4 | 90.0 | 98.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Motilal Oswal | ▲ Buy | 2,570 | 05-Aug-2026 |
| HSBC | ▲ Buy | 2,590 | 04-Aug-2026 |
| ICICI Securities | ► Hold | 2,100 | 04-Aug-2026 |
| Choice Equity | ▲ Buy | 2,590 | 17-Jun-2026 |
| Investec | ▲ Buy | 2,750 | 11-Jun-2026 |
| Deven Choksey | ► Add | 2,410 | 10-Jun-2026 |
Company Overview
Show Company Profile
Glenmark Pharmaceuticals Limited, together with its subsidiaries, research, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides various products in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetes, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, and respiratory-metered dose inhaler, dry powder inhaler, and nasal sprays. Its product pipeline includes ISB 2001, a CD38 x BCMA x CD3 trispecific T cell engager, which is in Phase 1 clinical trial for indication of multiple myeloma; ISB 2301, a Multispecific Immune Cell Activator that is in preclinical trial for solid tumors; ISB 2302, a bispecific immune modulator with an indication for hematologic and solid tumors; and ISB 2501, a trispecific T-cell engager indicated for solid tumors. The company's pipeline also comprises ISB 880, an IL-1RAP antagonist monoclonal antibody, which is in Phase 2 clinical trial for the treatment of hidradenitis suppurativa; and telazorlimab and ISB 830-X8, a OX40 antagonist mAb for the treatment of atopic dermatitis. In addition, the company offers Ryaltris, fixed-dose nasal spray for the treatment of allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.